- Factor to reveal engineered iPSC-derived macrophages that
enhance T cell cytotoxicity to triple negative breast and ovarian
cancer cells
- Presentations will include latest preclinical data from
Factor's stealth iPSC and nucleic acid delivery platforms
CAMBRIDGE, Mass., July 9, 2024
/PRNewswire/ -- Factor Bioscience Inc., a Cambridge-based biotechnology company focused
on developing mRNA and cell-engineering
technologies, announced its participation in the International
Society for Stem Cell Research (ISSCR) 2024 Annual Meeting to be
held in Hamburg, Germany from
July 10-13, 2024. Factor will deliver
six presentations covering the latest preclinical data from
Factor's cell engineering platforms.
The work that we will be presenting this
week represents more than a decade of focused effort.
"We are excited to showcase our recent progress on developing
next-generation therapies based on cutting-edge stem cell science
at ISSCR 2024," said Dr. Matt Angel,
Co-Founder, Chairman and CEO of Factor. "The work that we will be
presenting this week represents more than a decade of focused
effort. We are committed to developing these new medicines to
enable a brighter future for patients and their families."
Dr. Kyle Garland, Factor's
Director of Translational Science, added, "Our six presentations at
ISSCR 2024 will cover several novel and unique stem cell
technologies, including iPSC-derived macrophages engineered with
mRNA to enhance T cell cytotoxicity to solid tumor cells. We are
excited to share these and other advances in Hamburg over the next few days."
Details of the presentations are below:
- "Engineered iPSC-Derived Macrophages Evade
Host-Versus-Graft Alloreactivity and Enhance T Cell Cytotoxicity to
Triple Negative Breast and Ovarian Cancer Cells In Vitro." -to be
presented by Ian Hay on July 12 from 1:30-3:00 pm
CEST, PSC-Based Cell Therapies Session (Oral Presentation),
Hall 3 - Entrance Level.
- "B2M-KO iMSCs Better Suppress T Cell Proliferation by
Upregulating IDO1 in Response to Proinflammatory Signals." -to be
presented by Raven Dance Hinkel on
July 10 from 5:45-6:45 pm CEST, Clinical Applications (CA)
Session I: (Poster Presentation #165), Hall H - Entrance Level.
- "Donor-Sequence Optimization Enables Targeted Insertion of
Complex Stealthing Constructs in mRNA-Reprogrammed Induced
Pluripotent Stem Cells." -to be presented by Elizabeth Belcher on July
10 from 6:45-7:45 pm CEST,
Clinical Applications (CA) Session I: (Poster Presentation #228),
Hall H - Entrance Level.
- "Novel Polyvalent Ionizable Lipids Enable Targeted
Delivery of mRNA to Immune Cells and iPSC-derived MSCs." -to be
presented by Ariadna Lubinus on
July 11 from 3:45-4:45 pm CEST, New Technologies (NT) Session
II: (Poster Presentation #509), Hall H - Entrance Level.
- "Novel Regulatory Sequences Drive Persistent Transgene
Expression During Directed Differentiation of iPSCs to Lymphocytes
and Macrophages." -to be presented by Claire Aibel on July
11 from 4:45-5:45 pm CEST, New
Technologies (NT) Session II: (Poster Presentation #368), Hall H -
Entrance Level.
- "Reporter-Free Generation of iPSC-derived Tissue-Specific
Cells Engineered for the Stable Expression of Immunomodulatory
Proteins." -to be presented by Taeyun
Kim on July 11 from
4:45-5:45 pm CEST, New Technologies
(NT) Session II: (Poster Presentation #394), Hall H - Entrance
Level.
For more information about the International Society for Stem
Cell Research (ISSCR) 2024 Annual Meeting, visit
www.isscr2024.org.
About Factor Bioscience
Founded in 2011, Factor
Bioscience engineers cells to promote health and improve lives.
Factor Bioscience is privately held and headquartered in
Cambridge, MA. For more
information, visit www.factorbio.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/factor-bioscience-to-deliver-six-presentations-at-the-international-society-for-stem-cell-research-isscr-2024-annual-meeting-302191403.html
SOURCE Factor Bioscience